Veradigm Inc
Change company Symbol lookup
Select an option...
MDRX Veradigm Inc
CNXA Connexa Sports Technologies Inc
MORF Morphic Holding Inc
STOK Stoke Therapeutics Inc
DUOT Duos Technologies Group Inc
BCLI Brainstorm Cell Therapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
SBFM Sunshine Biopharma Inc
SEKEY Seiko Epson Corp
Go

*Nasdaq FSI: *Delinquent: Issuer Missed Regulatory Filing Deadline

Health Care : Health Care Technology | Small Cap Blend
Company profile

Veradigm, Inc., formerly Allscripts Healthcare Solutions, Inc., delivers healthcare information technology (IT) solutions to help healthcare organizations achieve clinical, financial and operational results. The Company's solutions helps to connect people, places and data across an Open Connected Community of Health. It offers payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Veradigm also offers software applications for patient engagement and the sale of electronic health record (EHR) software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions.

Closing Price
$12.58
Day's Change
-0.04 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
12.67
Day's Low
12.44
Volume
(Light)
Volume:
717,200

10-day average volume:
1,150,172
717,200

Company Profile

Veradigm, Inc., formerly Allscripts Healthcare Solutions, Inc., delivers healthcare information technology (IT) solutions to help healthcare organizations achieve clinical, financial and operational results. The Company's solutions helps to connect people, places and data across an Open Connected Community of Health. It offers payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Veradigm also offers software applications for patient engagement and the sale of electronic health record (EHR) software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions.

Valuation Ratios

Price/Earnings (TTM)
13.42x
Price/Sales (TTM)
1.65x
Price/Book (MRQ)
1.17x
Price/Cash Flow (TTM)
6.71x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

August 2023
Current Month
8.3M
Previous Month
8.5M
Percent of Float
7.82%
Days to Cover
11.7894 Days

Share Information

MDRX is in a share class of common stock
Float
106.6M
Shares Outstanding
109.3M
Institutions Holding Shares
323
102.65%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Thomas LanganPres.
  • Richard J. PoultonCEO
  • Leah JonesCFO
  • Lisa Hammond
  • Tejal VakhariaSr.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.